Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Rhea-AI Summary
Treace Medical Concepts (Nasdaq: TMCI) reported Q4 2025 revenue of $62.5M and full-year 2025 revenue of $212.7M (up 2% year-over-year). Q4 net loss was $9.4M and full-year net loss was $59.0M. Adjusted EBITDA improved to a $3.9M loss for 2025 from $11.0M in 2024.
Cash and marketable securities totaled $48.4M at year-end and the company has an additional $115M credit facility. Full-year 2026 guidance: revenue $200M–$212M, Adjusted EBITDA loss $4M–$6M, and ~50% reduction in cash usage versus 2025.
Positive
- Revenue +2% YoY to $212.7M in 2025
- Adjusted EBITDA loss improved 64% to $(3.9)M in 2025
- Cash usage reduced 46% to $27.3M in 2025
- Active surgeons +202 net new to 3,337 (6% increase)
Negative
- Q4 revenue declined 9% YoY to $62.5M
- Full-year net loss widened to $(59.0)M in 2025
- Gross margin down to 79.8% in 2025 from 80.4% in 2024
- 2026 revenue guidance implies up to a 6% decline versus 2025
Key Figures
Market Reality Check
Peers on Argus
TMCI gained 2.94% alongside peers in Surgical/Medical Devices: KIDS +6.02%, BVS +1.61%, CBLL +3.03%, CTKB +0.69%, SRDX +0.26%, suggesting a supportive sector backdrop.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings timing update | Neutral | -2.1% | Announced date and time for Q4 and full-year 2025 earnings release. |
| Nov 06 | Q3 2025 earnings | Negative | -28.3% | Reported 11% revenue growth but cut 2025 revenue and EBITDA guidance. |
| Aug 07 | Q2 2025 earnings | Positive | +7.9% | Posted 7% revenue growth and improved losses, maintained 2025 guidance. |
| May 08 | Q1 2025 earnings | Positive | -9.6% | Showed revenue growth and better net loss while reaffirming 2025 outlook. |
| Feb 27 | FY 2024 earnings | Positive | -2.1% | Delivered double‑digit 2024 growth and initial 2025 guidance with EBITDA goal. |
Earnings-related news has historically produced an average move of -6.83%, with sharp downside reactions when guidance is cut and mixed reactions even on growth quarters.
Over the past year, Treace’s earnings reports have shown modest revenue growth and improving Adjusted EBITDA, but guidance resets have weighed on sentiment. Q1 and Q2 2025 delivered low‑single‑digit to high‑single‑digit revenue growth and better losses, while Q3 2025 included a guidance cut and saw a -28.33% reaction. The 2024 full‑year release featured double‑digit growth and initial 2025 growth guidance, yet the stock still traded down. Today’s full‑year 2025 results and 2026 outlook follow that trajectory of improving efficiency but pressured growth expectations.
Historical Comparison
In the past year, TMCI released 5 earnings-related updates with an average move of -6.83%. Those often paired modest growth and EBITDA improvement with guidance pressure, a backdrop similar to this full-year 2025 report and 2026 outlook.
Across 2025, Treace reported modest quarterly revenue growth and steady gross margins while progressively lowering full-year 2025 guidance in November. The latest report closes 2025 with $212.7M revenue and a narrowed Adjusted EBITDA loss, but introduces 2026 guidance that implies flat to declining revenue versus 2025.
Market Pulse Summary
This announcement delivers Q4 2025 revenue of $62.5M, a 9% decline, and full-year 2025 revenue of $212.7M with a narrowed Adjusted EBITDA loss of $(3.9)M. Cash, equivalents, and marketable securities stood at $48.4M, with 2025 cash usage reduced to $27.3M. However, 2026 revenue guidance of $200M–$212M implies flat to lower growth as mix shifts toward lower-priced kits. Investors may track case volumes, pricing mix, and execution on new product launches to gauge whether growth can re-accelerate.
Key Terms
adjusted ebitda financial
non-gaap financial measures financial
gaap financial
credit facility financial
AI-generated analysis. Not financial advice.
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.
Recent Highlights
- Generated revenue of
$62.5 million in fourth quarter 2025 and revenue of$212.7 million for the full-year 2025, an increase of2% compared to the prior year. - Reported fourth quarter 2025 net loss of
$(9.4) million and adjusted EBITDA of$6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of$(59.0) million compared to a full-year net loss of$(55.7) million in 2024, reduced adjusted EBITDA loss by64% to$(3.9) million in the full-year 2025 compared to$(11.0) million in the same period in 2024. - Reduced cash usage by
46% to$27.3 million in full year 2025 compared to$50.5 million in full year 2024. - Increased net new active surgeons by 202 for full-year 2025 and ended the year with 3,337 active surgeons, a
6% increase compared to the prior year and33% of the estimated 10,000 U.S. surgeons performing bunion surgery. - Broadened global patent portfolio now totaling 135 granted patents in addition to 199 pending patent applications.
“During the fourth quarter, we improved upon the mid-single digit case volume growth that we experienced in the third quarter. This was driven by increasing demand for our comprehensive suite of 3D bunion correction systems by our growing base of over 3,300 surgeon customers,” said John T. Treace, CEO and Chairman of Treace. “In 2026, we expect our expanded bunion portfolio and forthcoming product launches to deliver continued market share gains and restore topline growth in the back half of the year.”
Fourth Quarter 2025 Financial Results
Revenue for the fourth quarter of 2025 was
Gross profit for the fourth quarter of 2025 was
Total operating expenses were
Fourth quarter 2025 net loss was
Full-Year 2025 Financial Results
Revenue for the full-year 2025 was
Gross profit for the full-year 2025 was
Total operating expenses were
Full-year 2025 net loss was
Cash, cash equivalents, and marketable securities totaled
2026 Financial Outlook
The Company is initiating full-year 2026 revenue guidance of
The Company expects a loss in Adjusted EBITDA in the range of
The Company expects a reduction in cash usage of approximately
The Company’s full-year 2026 guidance reflects continued case volume growth, offset by previously disclosed headwinds from demand driven product and price mix shift within Treace’s expanded bunion portfolio.
Webcast and Conference Call Details
Treace will host a conference call today, February 27, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full-year 2025 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.
*A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.
Forward-Looking Statements
This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: 2026 full-year guidance; anticipated liquidity; 2026 Adjusted EBITDA guidance; expected 2026 cash usage decrease; anticipated restoration of revenue growth in the back half of the year; expected increase in product adoptions; continued execution of strategic initiatives; anticipated market position, growth rates and profitability improvement; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to increased competition, evolving surgeon and patient preferences for minimally invasive bunion solutions, changes in tariff and trade policies, protracted government shutdowns, lower patient demand for elective bunion surgery due to macroeconomic uncertainty or soft consumer sentiment; anticipated future product launches and the timing of such product launches; ability to increase procedure volumes, expand surgeon relationships and utilization rate, and increase procedure penetration and market share; sufficiency of its balance sheet to continue executing strategic and growth initiatives for the foreseeable future; anticipated expansion of clinical evidence; ability to protect and enforce its intellectual property rights, including through its patent infringement and unfair competition suits; success in defending against securities class actions and infringement of its intellectual property by third parties, including its competitors; expected seasonality; ability to leverage investments in its commercial organization and control costs in its organizational structure, the amount and timing of orders for our products from stocking distributors and other customers; and anticipated pace of growth in the foot and ankle market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the year ended December 31, 2025, are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP® System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
| Treace Medical Concepts, Inc. Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 62,519 | $ | 68,708 | $ | 212,690 | $ | 209,357 | ||||||||
| Cost of goods sold | 12,118 | 13,231 | 42,938 | 41,093 | ||||||||||||
| Gross profit | 50,401 | 55,477 | 169,752 | 168,264 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 37,253 | 36,859 | 140,880 | 147,643 | ||||||||||||
| Research and development | 4,542 | 5,210 | 20,282 | 20,589 | ||||||||||||
| General and administrative | 14,528 | 13,612 | 62,744 | 55,720 | ||||||||||||
| Total operating expenses | 56,323 | 55,681 | 223,906 | 223,952 | ||||||||||||
| Loss from operations | (5,922 | ) | (204 | ) | (54,154 | ) | (55,688 | ) | ||||||||
| Interest income | 527 | 899 | 2,777 | 4,877 | ||||||||||||
| Interest expense | (1,350 | ) | (1,314 | ) | (5,320 | ) | (5,256 | ) | ||||||||
| Debt extinguishment loss | (2,737 | ) | — | (2,737 | ) | — | ||||||||||
| Other income, net | 88 | 118 | 432 | 324 | ||||||||||||
| Other non-operating income (expense), net | (3,472 | ) | (297 | ) | (4,848 | ) | (55 | ) | ||||||||
| Net loss | $ | (9,394 | ) | $ | (501 | ) | $ | (59,002 | ) | $ | (55,743 | ) | ||||
| Other comprehensive income (loss) | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | $ | (11 | ) | $ | (94 | ) | $ | (25 | ) | $ | (66 | ) | ||||
| Comprehensive loss | $ | (9,405 | ) | $ | (595 | ) | $ | (59,027 | ) | $ | (55,809 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.15 | ) | $ | (0.01 | ) | $ | (0.93 | ) | $ | (0.90 | ) | ||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 63,860,088 | 62,340,603 | 63,269,003 | 62,112,037 | ||||||||||||
| Treace Medical Concepts, Inc. Balance Sheets (in thousands, except share and per share amounts) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 10,708 | $ | 11,350 | ||||
| Marketable securities, short-term | 37,659 | 64,327 | ||||||
| Accounts receivable, net of allowance for credit losses of | 42,155 | 40,803 | ||||||
| Inventories | 36,031 | 39,255 | ||||||
| Prepaid expenses and other current assets | 5,501 | 5,667 | ||||||
| Total current assets | 132,054 | 161,402 | ||||||
| Property and equipment, net | 29,752 | 25,953 | ||||||
| Intangible assets, net of accumulated amortization of | 7,125 | 8,075 | ||||||
| Goodwill | 12,815 | 12,815 | ||||||
| Operating lease right-of-use assets | 7,614 | 8,442 | ||||||
| Other non-current assets, net of allowance for credit losses of | 1,221 | 407 | ||||||
| Total assets | $ | 190,581 | $ | 217,094 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 6,726 | $ | 10,522 | ||||
| Accrued liabilities | 5,784 | 7,197 | ||||||
| Accrued commissions | 9,365 | 10,121 | ||||||
| Accrued compensation | 6,331 | 6,575 | ||||||
| Other liabilities | 2,429 | 510 | ||||||
| Total current liabilities | 30,635 | 34,925 | ||||||
| Long-term debt, net | 55,583 | 53,306 | ||||||
| Operating lease liabilities, net of current portion | 13,982 | 15,934 | ||||||
| Other long-term liabilities | 3,049 | 37 | ||||||
| Total liabilities | 103,249 | 104,202 | ||||||
| Commitments and contingencies (Note 8) | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 64 | 62 | ||||||
| Additional paid-in capital | 337,371 | 303,004 | ||||||
| Accumulated deficit | (248,992 | ) | (189,990 | ) | ||||
| Accumulated other comprehensive income (loss) | 72 | 97 | ||||||
| Treasury stock, at cost; 165,513 and 23,391 shares as of December 31, 2025 and December 31, 2024, respectively | (1,183 | ) | (281 | ) | ||||
| Total stockholders’ equity | 87,332 | 112,892 | ||||||
| Total liabilities and stockholders’ equity | $ | 190,581 | $ | 217,094 | ||||
| Treace Medical Concepts, Inc. Statements of Cash Flows (in thousands) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (59,002 | ) | $ | (55,743 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||||||
| Depreciation and amortization expense | 10,623 | 8,419 | ||||||
| Provision for allowance for credit losses | 834 | 2,947 | ||||||
| Share-based compensation expense | 33,823 | 30,603 | ||||||
| Non-cash lease expense | 2,222 | 2,349 | ||||||
| Amortization of debt issuance costs | 292 | 298 | ||||||
| Debt extinguishment loss | 2,737 | — | ||||||
| Amortization (accretion) of premium (discount) on marketable securities, net | (123 | ) | (1,145 | ) | ||||
| Other, net | 1,208 | 538 | ||||||
| Net changes in operating assets and liabilities, net of acquisitions | ||||||||
| Accounts receivable | (2,090 | ) | (5,687 | ) | ||||
| Inventory | 3,224 | (10,010 | ) | |||||
| Prepaid expenses and other assets | 166 | 2,186 | ||||||
| Other non-current assets | (503 | ) | (330 | ) | ||||
| Operating lease liabilities | (3,207 | ) | (2,473 | ) | ||||
| Accounts payable | (3,796 | ) | (1,313 | ) | ||||
| Accrued liabilities | (2,413 | ) | (7,903 | ) | ||||
| Other, net | 35 | 97 | ||||||
| Net cash provided by (used in) operating activities | (15,970 | ) | (37,167 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of available-for-sale marketable securities | (40,571 | ) | (71,579 | ) | ||||
| Sales and maturities of available-for-sale marketable securities | 67,339 | 118,547 | ||||||
| Purchases of property and equipment | (13,517 | ) | (11,593 | ) | ||||
| Net cash provided by (used in) investing activities | 13,251 | 35,375 | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from interest bearing term debt | 59,310 | — | ||||||
| Proceeds from insurance premium financing | 1,553 | — | ||||||
| Debt issuance costs | (1,199 | ) | — | |||||
| Payments on interest bearing term and revolving debt | (56,315 | ) | — | |||||
| Payments on insurance premium financing | (916 | ) | — | |||||
| Proceeds from exercise of employee stock options | 546 | 428 | ||||||
| Taxes from withheld shares | (902 | ) | (268 | ) | ||||
| Net cash provided by (used in) financing activities | 2,077 | 160 | ||||||
| Net increase (decrease) in cash and cash equivalents | (642 | ) | (1,632 | ) | ||||
| Cash and cash equivalents at beginning of period | 11,350 | 12,982 | ||||||
| Cash and cash equivalents at end of period | $ | 10,708 | $ | 11,350 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 4,997 | $ | 4,955 | ||||
| Operating lease right-of-use asset and lease liability adjustment due to lease incentive | $ | — | $ | 8 | ||||
| Noncash investing activities | ||||||||
| Unrealized (gains) losses, net on marketable securities | $ | 25 | $ | 66 | ||||
| Noncash financing activities | ||||||||
| Legal cost financing | $ | 1,108 | $ | — | ||||
| Treace Medical Concepts, Inc. Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA (in thousands) (unaudited) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net loss | $ | (9,394 | ) | $ | (501 | ) | $ | (59,002 | ) | $ | (55,743 | ) | |||
| Adjustments: | |||||||||||||||
| Interest income | (527 | ) | (899 | ) | (2,777 | ) | (4,877 | ) | |||||||
| Interest expense | 1,350 | 1,314 | 5,320 | 5,256 | |||||||||||
| Taxes | — | — | — | — | |||||||||||
| Depreciation & Amortization | 2,808 | 2,237 | 10,623 | 8,419 | |||||||||||
| EBITDA | $ | (5,763 | ) | $ | 2,151 | $ | (45,836 | ) | $ | (46,945 | ) | ||||
| Share-based compensation expense | 7,555 | 8,555 | 33,823 | 30,603 | |||||||||||
| Acquisition-related costs | — | — | — | 1,873 | |||||||||||
| Restructuring costs1 | 352 | — | 1,529 | 964 | |||||||||||
| Customer credit loss2 | — | — | — | 2,147 | |||||||||||
| Litigation costs3 | 1,304 | 399 | 3,852 | 399 | |||||||||||
| Debt extinguishment loss | 2,737 | — | 2,737 | — | |||||||||||
| Adjusted EBITDA | $ | 6,185 | $ | 11,105 | $ | (3,895 | ) | $ | (10,959 | ) | |||||
1 Restructuring charges primarily relate to severance payments and other post-employment benefits from a restructuring in the second quarter of 2024 and the third quarter and fourth quarter of 2025.
2 Customer credit loss consists of the write-off of accounts receivable due from a customer that filed for bankruptcy during the second quarter of 2024.
3 Litigation costs relate to patent infringement lawsuits.
FAQ
What were Treace (TMCI) Q4 2025 results and how did revenue compare to Q4 2024?
How did Treace (TMCI) perform for full-year 2025 on revenue and adjusted EBITDA?
What is Treace's (TMCI) cash position and liquidity as of December 31, 2025?
What guidance did Treace (TMCI) provide for full-year 2026 revenue and Adjusted EBITDA?
How did Treace (TMCI) change cash usage and surgeon base in 2025?
Why did Treace (TMCI) report a higher net loss in 2025 despite improved Adjusted EBITDA?
